dual glp-1/gip agonist | Tirzepatide | Obesity & T2DM Mx | Harrison's Update(22nd Ed.) Free Comparison Chart: GLP-1 and

Due to the heterogeneity presented in the included studies (I 2 = 66%, P = 0.05), we used the random effects model (Fig

[3] [5] For patients with LDL-C 190 mg/dL, high-intensity statins are first-line therapy, with consideration of ezetimibe, bempedoic acid, or PCSK9 inhibitors for additional lowering

Researchers should consult the full Phase 2 safety data and any updated Phase 3 findings when designing research protocols involving this compound

GLP-1R causes a reduction in hepatic steatosis and inflammation and increases fat metabolism mediated by increasing hepatic insulin sensitivity [52,53,54]

doi: 10.1016/S0025-7753(14)70101-0